Too-Big-To-Fail As A Shadow Poison Pill – ValueWalk Premium
moody Too-Big-To-Fail ratings

Too-Big-To-Fail As A Shadow Poison Pill

Aside from putting the economy at risk (and taxpayers in particular), banks that are seen as too big to fail have an unfair advantage over smaller banks because the perceived government backstop reduces their funding costs. Harvard Law School professor Mark Roe argues that the too-big-to-fail subsidy also acts as a ‘shadow poison pill’ that makes corporate restructuring a losing proposition.

“An operationally successful restructuring of such a too-big-to-fail financial firm will increase the . . .


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email or click Chat.

Saved Articles
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.